JP2001527066A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001527066A5 JP2001527066A5 JP2000526484A JP2000526484A JP2001527066A5 JP 2001527066 A5 JP2001527066 A5 JP 2001527066A5 JP 2000526484 A JP2000526484 A JP 2000526484A JP 2000526484 A JP2000526484 A JP 2000526484A JP 2001527066 A5 JP2001527066 A5 JP 2001527066A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- group
- groups
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 34
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 27
- 229910052757 nitrogen Inorganic materials 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 20
- 125000004433 nitrogen atom Chemical group N* 0.000 description 19
- 239000001257 hydrogen Substances 0.000 description 18
- 229910052739 hydrogen Inorganic materials 0.000 description 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- -1 CF 3 Chemical group 0.000 description 8
- 125000004076 pyridyl group Chemical group 0.000 description 8
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 5
- 125000001624 naphthyl group Chemical group 0.000 description 5
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 4
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 239000002243 precursor Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229920001577 copolymer Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97122901 | 1997-12-24 | ||
| EP97122901.8 | 1997-12-24 | ||
| PCT/EP1998/008030 WO1999033800A1 (en) | 1997-12-24 | 1998-12-10 | Indole derivatives as inhibitors or factor xa |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001527066A JP2001527066A (ja) | 2001-12-25 |
| JP2001527066A5 true JP2001527066A5 (https=) | 2006-02-02 |
| JP4589529B2 JP4589529B2 (ja) | 2010-12-01 |
Family
ID=8227884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000526484A Expired - Fee Related JP4589529B2 (ja) | 1997-12-24 | 1998-12-10 | Ｘａ因子阻害剤としてのインドール誘導体 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6337344B1 (https=) |
| EP (1) | EP1042287B1 (https=) |
| JP (1) | JP4589529B2 (https=) |
| KR (1) | KR100608472B1 (https=) |
| CN (1) | CN1220681C (https=) |
| AR (1) | AR018031A1 (https=) |
| AT (1) | ATE293599T1 (https=) |
| AU (1) | AU743881B2 (https=) |
| BR (1) | BR9814340B1 (https=) |
| CA (1) | CA2316172C (https=) |
| CZ (1) | CZ298827B6 (https=) |
| DE (1) | DE69829879T2 (https=) |
| DK (1) | DK1042287T3 (https=) |
| ES (1) | ES2241194T3 (https=) |
| HU (1) | HU227568B1 (https=) |
| ID (1) | ID27044A (https=) |
| IL (1) | IL136954A0 (https=) |
| MY (1) | MY120064A (https=) |
| NO (1) | NO316912B1 (https=) |
| NZ (1) | NZ505370A (https=) |
| PL (1) | PL195682B1 (https=) |
| PT (1) | PT1042287E (https=) |
| RU (1) | RU2225397C2 (https=) |
| SI (1) | SI1042287T1 (https=) |
| TR (1) | TR200001954T2 (https=) |
| TW (1) | TWI241294B (https=) |
| WO (1) | WO1999033800A1 (https=) |
| ZA (1) | ZA9811759B (https=) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9716657D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| HU227568B1 (en) * | 1997-12-24 | 2011-08-29 | Sanofi Aventis Deutschland | Indole derivatives, as inhibitors os factor xa |
| GB9803226D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| DE19917504A1 (de) * | 1999-04-17 | 2000-10-19 | Dresden Arzneimittel | Verwendung von Hydroxyindolen, die Inhibitoren der Phosphodiesterase 4 sind, zur Therapie chronisch obstruktiver Lungenerkrankungen |
| KR20010101355A (ko) | 1999-01-02 | 2001-11-14 | 로버트 흐라이탁, 미쉘 베스트 | 신규한 말론산 유도체, 이의 제조 방법, 이의 용도 및이를 함유하는 약제학적 조성물(인자 ｘａ 활성 억제) |
| JP2002534408A (ja) | 1999-01-02 | 2002-10-15 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | アリールアルカノイル誘導体、その調製のための方法、その使用およびそれらを含有する医薬組成物 |
| GB9902459D0 (en) * | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902455D0 (en) * | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902461D0 (en) * | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902453D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902452D0 (en) * | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| CO5370679A1 (es) * | 1999-06-01 | 2004-02-27 | Smithkline Beecham Corp | Inhibidores fab 1 |
| EP1095933A1 (en) | 1999-10-30 | 2001-05-02 | Aventis Pharma Deutschland GmbH | Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
| GB0000625D0 (en) | 2000-01-13 | 2000-03-01 | Zeneca Ltd | Chemical compounds |
| EP1127884A1 (en) | 2000-02-26 | 2001-08-29 | Aventis Pharma Deutschland GmbH | Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them |
| GB0005366D0 (en) * | 2000-03-06 | 2000-04-26 | Xenova Ltd | Pharmaceutical compounds |
| US6548517B2 (en) | 2000-03-24 | 2003-04-15 | Millennium Pharmaceuticals, Inc. | Oxindole inhibitors of factor Xa |
| AU2001271531A1 (en) | 2000-06-27 | 2002-01-08 | Smith Kline Beecham Corporation | Fatty acid synthase inhibitors |
| WO2002026712A2 (en) * | 2000-09-29 | 2002-04-04 | Millennium Pharmaceuticals, Inc. | Quaternary amines and related inhibitors of factor xa |
| SK287806B6 (sk) | 2001-06-28 | 2011-10-04 | Pfizer Products Inc. | Triamid-substituované indoly, benzofurány a benzotiofény ako inhibítory mikrozómového proteínu prenášajúceho triglyceridu (MTP) a/alebo sekrécie apolipoproteínu B (Apo B) |
| DE10147672A1 (de) * | 2001-09-27 | 2003-04-10 | Bayer Ag | Substituierte 2,5-Diamidoindole und ihre Verwendung |
| EP1314733A1 (en) * | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
| CA2477604A1 (en) | 2002-03-13 | 2003-09-25 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
| AU2003302238A1 (en) | 2002-12-03 | 2004-06-23 | Axys Pharmaceuticals, Inc. | 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors |
| US7317027B2 (en) * | 2003-05-19 | 2008-01-08 | Sanofi-Aventis Deutschland Gmbh | Azaindole-derivatives as factor Xa inhibitors |
| EP1479680A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Azaindole derivatives as Factor Xa inhibitors |
| EP1479677A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | New indole derivatives as factor xa inhibitors |
| WO2004108671A1 (en) * | 2003-06-06 | 2004-12-16 | Suven Life Sciences Limited | Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them |
| SE0302035D0 (sv) * | 2003-07-09 | 2003-07-09 | Biolipox Ab | New compound |
| EP1648867B1 (en) * | 2003-07-17 | 2013-09-04 | Plexxikon Inc. | Ppar active compounds |
| US7348338B2 (en) * | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
| US7186084B2 (en) * | 2003-11-19 | 2007-03-06 | General Electric Company | Hot gas path component with mesh and dimpled cooling |
| EP1568698A1 (en) * | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrole-derivatives as factor Xa inhibitors |
| RU2007101703A (ru) * | 2004-06-18 | 2008-07-27 | Биолипокс Аб (Se) | Индолы, полезные при лечении воспаления |
| MXPA06014535A (es) * | 2004-06-18 | 2007-06-05 | Biolipox Ab | Indoles utiles en el tratamiento de la inflamacion. |
| DE602005014233D1 (de) * | 2004-06-18 | 2009-06-10 | Biolipox Ab | Zur behandlung von entzündungen geeignete indole |
| DK1761519T3 (da) * | 2004-06-21 | 2008-07-21 | Hoffmann La Roche | Indolderivater som histaminreceptorantagonister |
| JP2008512364A (ja) * | 2004-09-06 | 2008-04-24 | エフ．ホフマン−ラ ロシュ アーゲー | ４−アミノメチルベンズアミジン誘導体及び第ＶＩＩａ因子阻害剤としてのその使用 |
| US7446210B2 (en) | 2004-10-26 | 2008-11-04 | Janssen Pharmaceutica N.V. | Factor Xa compounds |
| GB0428173D0 (en) * | 2004-12-23 | 2005-01-26 | Astrazeneca Ab | Compounds |
| FR2880625B1 (fr) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| JP2008527028A (ja) * | 2005-01-19 | 2008-07-24 | バイオリポックス エービー | 炎症の治療に有用なインドール類 |
| EP1841766A1 (en) * | 2005-01-19 | 2007-10-10 | Biolipox AB | Pyrrolopyridines useful in the treatment of inflammation |
| BRPI0519774A2 (pt) * | 2005-01-19 | 2009-02-10 | Biolipox Ab | composto ou um sal farmaceuticamente aceitÁvel do mesmo, formulaÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, mÉtodo de tratamento de uma doenÇa em que inibiÇço da atividade de um membro da famÍlia mapeg É desejada e/ou necessÁria, produto combinado, e, processo para a preparaÇço de um composto |
| JP2008527030A (ja) * | 2005-01-19 | 2008-07-24 | バイオリポックス エービー | 炎症の治療に有用なインドール類 |
| US20090069384A1 (en) * | 2005-01-19 | 2009-03-12 | Biolipox Ab | Thienopyrroles useful in the treatment of inflammation |
| US20080249091A1 (en) * | 2005-01-19 | 2008-10-09 | Benjamin Pelcman | Indoles Useful in the Treatment of Inflammation |
| US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| WO2006084033A1 (en) * | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| EP1747779A1 (en) | 2005-07-28 | 2007-01-31 | Laboratorios Del Dr. Esteve, S.A. | Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands |
| RU2419618C2 (ru) * | 2005-09-07 | 2011-05-27 | Плекссикон, Инк. | Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом) |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| ATE507222T1 (de) * | 2005-11-30 | 2011-05-15 | Hoffmann La Roche | 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren |
| JP5322935B2 (ja) * | 2006-07-31 | 2013-10-23 | アクティベサイト ファーマシューティカルズ インコーポレイティッド | 血漿カリクレインの阻害薬 |
| MY150745A (en) * | 2006-09-13 | 2014-02-28 | Sanofi Aventis | Isoserine derivatives for use as coagulation factor ixa inhibitors |
| ES2452343T3 (es) * | 2006-09-29 | 2014-04-01 | Glaxosmithkline Llc | Compuestos de indol sustituidos |
| WO2008055808A1 (en) | 2006-11-09 | 2008-05-15 | F. Hoffmann-La Roche Ag | Indole and benzofuran 2-carboxamide derivatives |
| US8524917B2 (en) * | 2007-01-11 | 2013-09-03 | Allergan, Inc. | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
| PE20090159A1 (es) * | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
| WO2009023623A1 (en) * | 2007-08-10 | 2009-02-19 | H, Lundbeck A/S | Heteroaryl amide analogues |
| JP5607025B2 (ja) | 2008-04-21 | 2014-10-15 | シグナム バイオサイエンシーズ， インコーポレイテッド | 化合物、組成物およびそれらを作製する方法 |
| CN101654427B (zh) * | 2008-08-19 | 2012-12-05 | 信谊药厂 | 抗凝化合物、组合物及其用途 |
| US8546431B2 (en) | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US8575186B2 (en) | 2009-10-05 | 2013-11-05 | Albany Molecular Research, Inc. | Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof |
| US9206123B2 (en) | 2009-12-18 | 2015-12-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| EP2512466A4 (en) * | 2009-12-18 | 2013-07-03 | Activesite Pharmaceuticals Inc | PRODRUGS OF INHIBITORS OF PLASMATIC KALLICREIN |
| AU2012207335A1 (en) | 2011-01-19 | 2013-07-25 | Albany Molecular Research, Inc. | Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia |
| ES2587856T3 (es) | 2011-03-18 | 2016-10-27 | Ono Pharmaceutical Co., Ltd. | Derivado de tetrahidrocarbolina |
| WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| CN108602775B (zh) | 2016-01-14 | 2022-04-29 | 贝思以色列女会吏医学中心公司 | 肥大细胞调节剂及其用途 |
| AU2017263574B2 (en) | 2016-05-12 | 2022-11-17 | The Regents Of The University Of Michigan | ASH1L inhibitors and methods of treatment therewith |
| WO2019094772A1 (en) | 2017-11-10 | 2019-05-16 | The Regents Of The University Of Michigan | Ash1l degraders and methods of treatment therewith |
| WO2021229566A1 (en) | 2020-05-11 | 2021-11-18 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Compositions of tryptophol derivatives and 4-ethyl-phenol derivatives, and methods of using same |
| WO2023068700A1 (ko) * | 2021-10-20 | 2023-04-27 | 동국대학교 와이즈캠퍼스 산학협력단 | 두룸아마이드 a를 포함하는 혈소판 응집 예방, 개선 또는 치료용 조성물 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US997638A (en) * | 1910-08-13 | 1911-07-11 | Eugene Rynearson | Pavement-breaking machine. |
| US4529724A (en) * | 1983-10-11 | 1985-07-16 | Mcneilab, Inc. | 6H-indolo[2,1-c][1,4]benzodiazepines and 12-oxo derivatives useful as antihypertensives |
| DD235866B1 (de) | 1985-03-29 | 1988-12-28 | Univ Leipzig | Verfahren zur herstellung von n alpha (2-naphthyl)-sulfonylaminoacylierten amidinophenylalanisamiden |
| EP0639573A1 (de) * | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament |
| SI9520044B (sl) | 1994-04-26 | 2004-08-31 | Aventis Pharmaceuticals Inc. | Inhibitorji Xa faktorja |
| US5612363A (en) * | 1995-06-02 | 1997-03-18 | Berlex Laboratories, Inc. | N,N-di(aryl) cyclic urea derivatives as anti-coagulants |
| DE19530996A1 (de) | 1995-08-23 | 1997-02-27 | Boehringer Mannheim Gmbh | Cyclische Guanidine, Verfahren zu ihrer Herstellung und Arzneimittel |
| US5849759A (en) * | 1995-12-08 | 1998-12-15 | Berlex Laboratories, Inc. | Naphthyl-substituted benzimidazole derivatives as anti-coagulants |
| DE69717268T2 (de) | 1996-02-22 | 2003-09-04 | Bristol-Myers Squibb Pharma Co., Wilmington | M-amidinophenyl-analoga als faktor-xa-inhibitoren |
| US6200969B1 (en) * | 1996-09-12 | 2001-03-13 | Idun Pharmaceuticals, Inc. | Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
| US6184244B1 (en) * | 1996-12-16 | 2001-02-06 | Idun Pharmaceuticals, Inc. | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US5886191A (en) * | 1997-08-18 | 1999-03-23 | Dupont Pharmaceuticals Company | Amidinoindoles, amidinoazoles, and analogs thereof |
| HU227568B1 (en) * | 1997-12-24 | 2011-08-29 | Sanofi Aventis Deutschland | Indole derivatives, as inhibitors os factor xa |
-
1998
- 1998-12-10 HU HU0100723A patent/HU227568B1/hu not_active IP Right Cessation
- 1998-12-10 PL PL98341400A patent/PL195682B1/pl not_active IP Right Cessation
- 1998-12-10 AT AT98965244T patent/ATE293599T1/de active
- 1998-12-10 CN CNB988126532A patent/CN1220681C/zh not_active Expired - Fee Related
- 1998-12-10 KR KR1020007007084A patent/KR100608472B1/ko not_active Expired - Fee Related
- 1998-12-10 SI SI9830771T patent/SI1042287T1/xx unknown
- 1998-12-10 CA CA002316172A patent/CA2316172C/en not_active Expired - Fee Related
- 1998-12-10 ES ES98965244T patent/ES2241194T3/es not_active Expired - Lifetime
- 1998-12-10 AU AU20528/99A patent/AU743881B2/en not_active Ceased
- 1998-12-10 CZ CZ20002310A patent/CZ298827B6/cs not_active IP Right Cessation
- 1998-12-10 IL IL13695498A patent/IL136954A0/xx not_active IP Right Cessation
- 1998-12-10 RU RU2000119774/04A patent/RU2225397C2/ru not_active IP Right Cessation
- 1998-12-10 PT PT98965244T patent/PT1042287E/pt unknown
- 1998-12-10 DE DE69829879T patent/DE69829879T2/de not_active Expired - Lifetime
- 1998-12-10 DK DK98965244T patent/DK1042287T3/da active
- 1998-12-10 WO PCT/EP1998/008030 patent/WO1999033800A1/en not_active Ceased
- 1998-12-10 EP EP98965244A patent/EP1042287B1/en not_active Expired - Lifetime
- 1998-12-10 JP JP2000526484A patent/JP4589529B2/ja not_active Expired - Fee Related
- 1998-12-10 TR TR2000/01954T patent/TR200001954T2/xx unknown
- 1998-12-10 US US09/582,344 patent/US6337344B1/en not_active Expired - Lifetime
- 1998-12-10 NZ NZ505370A patent/NZ505370A/en not_active IP Right Cessation
- 1998-12-10 BR BRPI9814340-9A patent/BR9814340B1/pt not_active IP Right Cessation
- 1998-12-10 ID IDW20001225A patent/ID27044A/id unknown
- 1998-12-22 AR ARP980106607A patent/AR018031A1/es active IP Right Grant
- 1998-12-22 ZA ZA9811759A patent/ZA9811759B/xx unknown
- 1998-12-23 MY MYPI98005870A patent/MY120064A/en unknown
-
1999
- 1999-02-23 TW TW087121374A patent/TWI241294B/zh not_active IP Right Cessation
-
2000
- 2000-06-14 NO NO20003057A patent/NO316912B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001527066A5 (https=) | ||
| JP2024522345A (ja) | ウェルナー症候群ＲｅｃＱヘリカーゼ（ＷＲＮ）の阻害に関連する疾患を治療するためのトリアゾロ－ピリミジン類似体 | |
| JP5537085B2 (ja) | アリールビニルアザシクロアルカン化合物およびその調製方法ならびにその使用 | |
| RU2000119774A (ru) | Производные индола как ингибиторы фактора ха | |
| JP5579715B2 (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| CA2316172A1 (en) | Indole derivatives as inhibitors of factor xa | |
| EP4667464A1 (en) | Azolylpyridine pyridazinone amide as sos1 inhibitor | |
| HU228195B1 (hu) | Pirazolo-piridin gyûrût tartalmazó laktámok és származékaik, valamint az ezeket tartalmazó Xa faktor gátlására szolgáló gyógyszerkészítmények | |
| TW201625536A (zh) | 抑制組蛋白去甲基酶之化合物及方法 | |
| JP2018502900A (ja) | ジスコイジンドメイン受容体１を標的化する小分子阻害剤およびその使用 | |
| CN107001363B (zh) | 二氢吲嗪酮衍生物 | |
| CA3025722A1 (en) | Combinations comprising histone deacetylase inhibitors | |
| JP2010510999A5 (https=) | ||
| EP3083584B1 (en) | Nitrogenous heterocyclic derivatives and their application in the treatment of tissue fibrosis | |
| JP2003063994A (ja) | アルツハイマー病およびパーキンソン病に関連する痴呆または認識障害のための組合せ治療 | |
| JP2011526917A5 (https=) | ||
| JPS6360936A (ja) | 複合薬剤 | |
| ZA200105130B (en) | Bis-sulfonamides. | |
| RU2016123379A (ru) | Тетрагидротриазолопиримидиновые соединения в качестве ингибиторов нейтрофильной эластазы человека | |
| JP2003513066A5 (https=) | ||
| ES2676396T3 (es) | Moduladores alostéricos positivos del receptor de acetilcolina nicotínico | |
| JPH05506216A (ja) | 医薬としてのピリジン | |
| EP4653436A1 (en) | Heterocyclic compounds, preparation method therefor and use thereof | |
| JP2001520628A (ja) | 中枢神経系疾患の予防及び治療のための医薬組成物 | |
| CN107382840A (zh) | 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途 |